Medical management of urinary stone disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 8, 2007, Pages 1117-1125

  Park, Sangtae ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Kidney stones; Nephrolithiasis; Urinary stone disease

Indexed keywords

ACETOHYDROXAMIC ACID; ALLOPURINOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM OXALATE; CALCIUM PHOSPHATE; CAPTOPRIL; CELLULOSE PHOSPHATE; CHLORTALIDONE; CINACALCET; CITRATE POTASSIUM; CITRIC ACID; CORTICOSTEROID; DEFLAZACORT; DOXAZOSIN MESYLATE; GLUCONATE CALCIUM; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MISOPROSTOL; NIFEDIPINE; PENICILLAMINE; PLACEBO; POTASSIUM DIHYDROGEN PHOSPHATE; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; TIOPRONIN; UNINDEXED DRUG; URIC ACID;

ABDOMINAL PAIN; ASTHENIA; BLOATING; CHRONIC KIDNEY DISEASE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FLUID INTAKE; FLUID THERAPY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; HYPERCALCIURIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPEROXALURIA; HYPERURICEMIA; HYPERURICOSURIA; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; KIDNEY SURGERY; LEUKOPENIA; MACULOPAPULAR RASH; MEDICAL LITERATURE; METABOLIC PARAMETERS; MORBIDITY; MUSCLE CRAMP; NEPHROLITHIASIS; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PROTEIN RESTRICTION; PRURITUS; RECURRENT DISEASE; REVIEW; SODIUM RESTRICTION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREMOR; URINALYSIS; URINE PH; UROLITHIASIS; URTICARIA;

CRYSTALLIZATION; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY CALCULI; METABOLIC DISEASES; PREVALENCE; RECURRENCE; RISK FACTORS;

EID: 34250649707     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.8.1117     Document Type: Review

References (63)

1. PAK CY. Kidney stones. Lancet (1998) 351(9118):1797-1801.
2. PREMINGER. GM: Renal calculi: pathogenesis, diagnosis, and medical therapy. Semin. Nephrol. (1992) 12(2):200-216.
3. SIERAKOWSKI R, FINLAYSON B, LANDES RR, FINLAYSON CD, SIERAKOWSKI N: The frequency of urolithiasis in hospital discharge diagnoses in the United States. Invest. Urol. (1978) 15(6):438-441.
4. KREPINSKY J, INGRAM AJ, CHURCHILL DN: Metabolic investigation of recurrent nephrolithiasis: compliance with recommendations. Urology (2000) 56(6):915-920.
5. GLOWACKI LS, BEECROFT ML, COOK RJ, PAHL D, CHURCHILL DN: The natural history of asymptomatic urolithiasis. J. Urol. (1992) 147(2):319-321.
6. SHEKARRIZ B, STOLLER ML: Uric acid nephrolithiasis: current concepts and controversies. J. Urol. (2002) 168(4 Pt 1):1307-1314.
7. JUNGERS P, JOLY D, BARBEY F, CHOUKROUN G, DAUDON M: ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am. J. Kidney Dis. (2004) 44(5):799-805.
8. TISELIUS HG: Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease. BJU Int. (2001) 88(2):158-168.
9. Consensus conference. Prevention and treatment of kidney stones. JAMA (1988) 260(7):977-981.
10. OSTHER PJ, GRENABO L, HARALDSSON G et al.: Metabolic evaluation and medical management of upper urinary tract stone disease. Guidelines from the Scandinavian Cooperative Group for Urinary Stones. Scand J. Urol. Nepbrol. (1999) 33(6):372-381.
11. PAK CY, POINDEXTER JR, ADAMS-HUET B, PEARLE MS: Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am. J. Med. (2003) 115(1):26-32.
12. KOURAMBAS J, ASLAN P, TEH CL, MATHIAS BJ, PREMINGER. GM: Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J. Endourol. (2001) 15(2):181-186.
13. PAK CY, BRITTON F, PETERSON R et al.: Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am. J. Med. (1980) 69(1):19-30.
14. GROVER PK, RYALL RL: Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner. Electrolyte Metab. (1994) 20(6):361-370.
15. PAK CY. Citrate and renal calculi: an update. Miner. Electrolyte Metab. (1994) 20(6):371-377.
16. JENKINS AD, DOUSA TP, SMITH LH: Transport of citrate across renal brush border membrane: effects of dietary acid and alkali loading. Am. J. Physiol. (1985) 249(4 Pt 2):F590-F595.
17. COCHAT P, GAULIER JM, KOCH NOGUEIRA PC et al.: Combined liver-kidney transplantation in primary hyperoxaluria type 1. Eur. J. Pediatr. (1999) 158(Suppl 2):S75-A80.
18. EARNEST DL, WILLIAMS HE, ADMIRAND WH: A physicochemical basis for treatment of enteric hyperoxaluria. Trans. Assoc. Am. Physicians (1975) 88:224-234.
19. TRUS TL, POPE GD, FINLAYSON SR: National trends in utilization and outcomes of bariatric surgery. Surg. Endosc. (2005) 19(5):616-620.
20. ASPLIN J, COE F: Hyperoxaluria in bariatric surgery patients with urolithiasis' National American Urological Association meeting. Atlanta (GA) USA (20 - 25 May 2006) Abscr. 1040.
21. TRAXER O, HUET B, POINDEXTER J, PAK CY, PEARLE MS: Effect of ascorbic acid consumption on urinary stone risk factors. J. Urol. (2003) 170(2 Pt 0:397-401.
22. CURHAN GC, WILLETT WC, RIMM EB, STAMPFER MJ: A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J. Urol. (1996) 155(6):1847-1851.
23. CURHAN GC, WILLETT WC, SPEIZER FE, STAMPFER MJ: Intake of vitamins B6 and C and the risk of kidney stones in women. J. Am. Soc. Nephrol. (1999) 10(4):840-845.
24. LEVY FL, ADAMS-HUET B, PAK CY: Ambulatory evaluation of nephrolichiasis: an update of a 1980 protocol. Am. J. Med. (1995) 98(1):50-59.
25. MAALOUF NM, CAMERON MA, MOE OW, SAKHAEE K: Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr. Opin. Nephrol. Hypertens. (2004) 13(2):181-189.
26. NG CS, STREEM SB: Contemporary management of cystinuria. J. Endourol. (1999) 13(9):647-651.
27. RAHMAN NU, MENG MV, STOLLER ML: Infections and urinary stone disease. Curr. Pharm. Des. (2003) 9(12):975-981.
28. PORPIGLIA F, DESTEFANIS P, FIORI C, FONTANA D: Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology (2000) 56(4):579-582.
29. PORPIGLIA F, GHIGNONE G, FIORI C, FONTANA D, SCARPA RM: Nifedipine versus tamsulosin for the management of lower ureteral stones. J. Urol. (2004) 172(2):568-571.
30. DELLABELLA M, MILANESE G, MUZZONIGRO G: Efficacy of tamsulosin in the medical management of juxtavesical ureceral stones. J. Urol. (2003) 170(6 Pt 1):2202-2205.
31. DELLABELLA M, MILANESE G, MUZZONIGRO G: Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology (2005) 66(4):712-715.
32. DELLABELLA M, MILANESE G, MUZZONIGRO G: Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J. Urol. (2005) 174(1):167-172.
33. YILMAZ E, BATISLAM E, BASAR MM et al.: The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J. Urol. (2005) 173(6):2010-2012.
34. CURHAN GC, WILLETT WC, RIMM EB, STAMPFER MJ: A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N. Engl. J. Med. (1993) 328(12):833-838.
35. BORGHI L, MESCHI T, AMATO F et al.: Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J. Urol. (1996) 155(3):839-843.
36. GETTMAN MT, OGAN K, BRINKLEY LJ et al.: Effect of cranberry juice consumption on urinary stone risk factors. J. Urol. (2005) 174(2):590-594; quiz 801.
37. SELTZER MA, LOW RK, MCDONALD M, SHAMI GS, STOLLER ML: Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J. Urol. (1996) 156(3):907-909.
38. WABNER CL, PAK CY. Effect of orange juice consumption on urinary stone risk factors. J. Urol. (1993) 149(6):1405-1408.
39. SAKHAFE K, HARVEY JA, PADALINO PK, WHITSON P, PAK CY: The potential role of salt abuse on the risk for kidney stone formation. J. Urol. (1993) 150(2 Pt 1):310-312.
40. AMANZADEH J, GITOMER WL, ZERWEKH JE et al.; Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int. (2003) 64(6):2142-2149.
41. PAK CY, ODVINA CV, PEARLE MS et al.: Effect of dietary modification on urinary stone risk factors. Kidney Int. (2005) 68(5):2264-2273.
42. BROCKS P, DAHL C, WOLF H, TRANSBOL 1: Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet (1981) 2(8238):124-125.
43. SCHOLZ D, SCHWILLE PO, SIGEL A: Double-blind study with thiazide in recurrent calcium lithiasis. J. Urol. (1982) 128(5):903-907.
44. BORGHI L, MESCHI T, GUERRA A, NOVARINI A: Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium scone recurrences. J. Cardiovasc. Pharmacol. (1993) 22(Suppl 6):S78-S86.
45. ETTINGER B, CITRON JT, LIVERMORE B, DOLMAN LI: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J. Urol. (1988) 139(4):679-684.
46. LAERUM E, LARSEN S: Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med. Scand. (1984) 215(4):383-389.
47. OHKAWA M, TOKUNAGA S, NAKASHIMA T, ORITO M, HISAZUMI H: Thiazide treatment for calcium urolichiasis in patients with idiopathic hypercalciuria. Br. J. Urol. (1992) 69(6):571-576.
48. BACKMAN U, DANIELSON BG, JOHANSSON G, LJUNGHALL S, VAKSTROM B: Treatment of recurrent calcium stone formation with cellulose phosphate. J. Urol. (1980) 123(1):9-13.
49. HELLER HJ, REZA-ALBARRAN AA, BRESLAU NA, PAK CY Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. J. Urol. (1998) 159(5):1451-1455; discussion 1455-1456.
50. ETTINGER B, TANG A, CITRON JT, LIVERMORE B, WILLIAMS T: Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N. Engl. J. Med. (1986) 315(22):1386-1389.
51. HAMM LL, HERING-SMITH KS: Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol. Metab. Clin. North Am. (2002) 31(4):885-893, viii.
52. BARCELO P, WUHL O, SERVITGE E, ROUSAUD A, PAK CY Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolichiasis. J. Urol. (1993) 150(6):1761-1764.
53. HOFBAUER J, HOBARTH K, SZABO N, MARBERGER M: Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis - a prospective randomized study. Br. J. Urol. (1994) 73(4):362-365.
54. ETTINGER B, PAK CY, CITRON JT et al.: Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. (1997) 158(6):2069-2073.
55. SOYGUR T, AKBAY A, KUPELI S: Effect of potassium citrale therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J. Endourol. (2002) 16(3):149-152.
56. LINDELL A, DENNEBERG T, HELLGREN E, JEPPSSON JO, TISELIUS HG: Clinical course and cystine stone formation during tiopronin treatment. Urol. Res. (1995) 23(2):111-117.
57. GOLDFARB DS, COE FL, ASPLIN JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. (2006) 69(6):1041-1047.
58. STREEM SB, HALL P: Effect of captopril on urinary cystine excretion in homozygous cystinuria. J. Urol. (1989) 142(6):1522-1524.
59. GRIFFITH DP, GLEESON MJ, LEE H et al. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur. Urol. (1991) 20(3):243-247.
60. GRIFFITH DP, KHONSARI F, SKURNICK JH, JAMES KE: A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J. Urol. (1988) 140(2):318-324.
61. WILLIAMS JJ, RODMAN JS, PETERSON CM: A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N. Engl. J. Med. (1984) 311(12):760-764.
62. WALL I, TISELIUS HG, LARSSON L: Hemiacidrin: a useful component in the treatment of infectious renal stones. Eur. Urol. (1988) 15(1-2):26-30.
63. ANGERMEIER K, STREEM SB, YOSTA: Simplified infusion method for 10% hemiacidrin irrigation of renal pelvis. Urology (1993) 41(3):243-246.